Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

Real-World Outcomes Topic Center

Featured Article

Headshot of Adam Kittai, Ohio State University, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
12/14/2021
Maria Asimopoulos
In part two of this podcast series, Adam Kittai, MD, hematologist and assistant professor of medicine, Ohio State University, highlights findings from the CAPTIVATE study regarding the efficacy of ibrutinib vs placebo for disease-free...
In part two of this podcast series, Adam Kittai, MD, hematologist and assistant professor of medicine, Ohio State University, highlights findings from the CAPTIVATE study regarding the efficacy of ibrutinib vs placebo for disease-free...
In part two of this podcast...
12/14/2021
First Report Managed Care
Headshot of Adam Kittai, Ohio State University, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
12/14/2021
Maria Asimopoulos
In part one of this podcast series, Adam Kittai, MD, hematologist and assistant professor of medicine, Ohio State University, provides an overview of current research being conducted on chronic lymphocytic leukemia and discusses the results...
In part one of this podcast series, Adam Kittai, MD, hematologist and assistant professor of medicine, Ohio State University, provides an overview of current research being conducted on chronic lymphocytic leukemia and discusses the results...
In part one of this podcast...
12/14/2021
First Report Managed Care
Conference Insider
05/17/2019
Researchers recently found that patient-reported outcomes (PROs) were no different among patients treated with calcitonin gene-related peptide (CGRP) antagonists or onabotulinumtoxinA (ONA) for the indication of chronic migraine prophylaxis. 
Researchers recently found that patient-reported outcomes (PROs) were no different among patients treated with calcitonin gene-related peptide (CGRP) antagonists or onabotulinumtoxinA (ONA) for the indication of chronic migraine prophylaxis. 
Researchers recently found that...
05/17/2019
First Report Managed Care
Conference Insider
04/19/2019
Newer technology could improve chronic pain in patients utilizing spinal cord stimulation (SCS) systems according to science presented at the American Academy of Pain Medicine’s 2019 Annual Meeting.
Newer technology could improve chronic pain in patients utilizing spinal cord stimulation (SCS) systems according to science presented at the American Academy of Pain Medicine’s 2019 Annual Meeting.
Newer technology could improve...
04/19/2019
First Report Managed Care
Conference Insider
07/19/2018
A study presented at the 2018 Annual European Congress of Rheumatology (EULAR 2018) found that dose tapering of biologics was cost saving for the treatment of rheumatic diseases in a real-world setting.
A study presented at the 2018 Annual European Congress of Rheumatology (EULAR 2018) found that dose tapering of biologics was cost saving for the treatment of rheumatic diseases in a real-world setting.
A study presented at the 2018...
07/19/2018
First Report Managed Care

Newsfeed

Conference Insider
05/17/2019
Researchers recently found that patient-reported outcomes (PROs) were no different among patients treated with calcitonin gene-related peptide (CGRP) antagonists or onabotulinumtoxinA (ONA) for the indication of chronic migraine prophylaxis. 
Researchers recently found that patient-reported outcomes (PROs) were no different among patients treated with calcitonin gene-related peptide (CGRP) antagonists or onabotulinumtoxinA (ONA) for the indication of chronic migraine prophylaxis. 
Researchers recently found that...
05/17/2019
First Report Managed Care
Conference Insider
04/19/2019
Newer technology could improve chronic pain in patients utilizing spinal cord stimulation (SCS) systems according to science presented at the American Academy of Pain Medicine’s 2019 Annual Meeting.
Newer technology could improve chronic pain in patients utilizing spinal cord stimulation (SCS) systems according to science presented at the American Academy of Pain Medicine’s 2019 Annual Meeting.
Newer technology could improve...
04/19/2019
First Report Managed Care
Conference Insider
07/19/2018
A study presented at the 2018 Annual European Congress of Rheumatology (EULAR 2018) found that dose tapering of biologics was cost saving for the treatment of rheumatic diseases in a real-world setting.
A study presented at the 2018 Annual European Congress of Rheumatology (EULAR 2018) found that dose tapering of biologics was cost saving for the treatment of rheumatic diseases in a real-world setting.
A study presented at the 2018...
07/19/2018
First Report Managed Care

Literature Review

Literature Review
10/23/2023

Danielle Sposato

Danielle Sposato
Not only does SER-109 effectively treat CDI, but results show that it can even reduce recurrence. A major benefit when it comes to associated health care costs for patients.
Not only does SER-109 effectively treat CDI, but results show that it can even reduce recurrence. A major benefit when it comes to associated health care costs for patients.
Not only does SER-109...
10/23/2023
First Report Managed Care
Literature Review
10/16/2023

Danielle Sposato

Danielle Sposato
The SAPHYR trial has provided researchers with valuable insights into alternative treatment options for PMR due to its larger patient population. The effectiveness of sarilumab and the achieved rates of remission offer promise for enhancing...
The SAPHYR trial has provided researchers with valuable insights into alternative treatment options for PMR due to its larger patient population. The effectiveness of sarilumab and the achieved rates of remission offer promise for enhancing...
The SAPHYR trial has provided...
10/16/2023
First Report Managed Care
Literature Review
12/06/2022
Edan Stanley
This article explores the incidence, prevalence, and management of Demodex Blepharitis.
This article explores the incidence, prevalence, and management of Demodex Blepharitis.
This article explores the...
12/06/2022
First Report Managed Care
Literature Review
11/29/2022
Maria Asimopoulos
Several ongoing and upcoming clinical trials are testing the efficacy and safety of a monoclonal antibody in combination with other therapies for multiple myeloma.
Several ongoing and upcoming clinical trials are testing the efficacy and safety of a monoclonal antibody in combination with other therapies for multiple myeloma.
Several ongoing and upcoming...
11/29/2022
First Report Managed Care
Literature Review
09/23/2022
Edan Stanley
This literature review explores the latest progression-free survival data for a multiple myeloma therapy option.
This literature review explores the latest progression-free survival data for a multiple myeloma therapy option.
This literature review explores...
09/23/2022
First Report Managed Care
Literature Review
09/16/2022
Edan Stanley
This literature review explores key data related to the epidemiology, clinical presentation, and treatment considerations for patients with low-grade upper tract urothelial carcinoma.
This literature review explores key data related to the epidemiology, clinical presentation, and treatment considerations for patients with low-grade upper tract urothelial carcinoma.
This literature review explores...
09/16/2022
First Report Managed Care
Literature Review
09/16/2021
Jeff Craven
In this literature review, we explore the data from the phase 3 VISION trial recently presented at the 2021 virtual annual meeting of the American Society of Clinical Oncology and published in the New England Journal of Medicine, examining...
In this literature review, we explore the data from the phase 3 VISION trial recently presented at the 2021 virtual annual meeting of the American Society of Clinical Oncology and published in the New England Journal of Medicine, examining...
In this literature review, we...
09/16/2021
First Report Managed Care
Literature Review
08/12/2021
Edan Stanley
For the purpose of this literature review, we examine the latest data presented at the American Academy of Neurology’s (AAN) 2021 Virtual Annual Meeting regarding the use of CBD for patients with seizure disorders including TSC.  
For the purpose of this literature review, we examine the latest data presented at the American Academy of Neurology’s (AAN) 2021 Virtual Annual Meeting regarding the use of CBD for patients with seizure disorders including TSC.  
For the purpose of this...
08/12/2021
First Report Managed Care
Literature Review
05/28/2021
Edan Stanley
With a newly proposed and easily applicable definition for dry eye disease, researchers believe the condition can be diagnosed with more consistency as well as inform future trials and research. 
With a newly proposed and easily applicable definition for dry eye disease, researchers believe the condition can be diagnosed with more consistency as well as inform future trials and research. 
With a newly proposed and easily...
05/28/2021
First Report Managed Care
Literature Review
02/12/2021

Edan Stanley

Edan Stanley
Per the American Migraine foundation, oral and intranasal triptan therapy has proven consistently effective when used to treat migraine earlier in the attack; however, triptan therapy is not effective for all patients with migraine and cannot...
Per the American Migraine foundation, oral and intranasal triptan therapy has proven consistently effective when used to treat migraine earlier in the attack; however, triptan therapy is not effective for all patients with migraine and cannot...
Per the American Migraine...
02/12/2021
First Report Managed Care

First Report

“While this dataset is still maturing, in this as-observed interim analysis of a real-world study, dupilumab demonstrated early and sustained improvement in AD flares, symptoms, and disea...
A recent study shows successful reduction of signs, symptoms, and severity of atopic dermatitis based on real-world patient data.

Advertisement

Advertisement

Advertisement